December 4, 2020
A key health ministry advisory panel recommended approval for Japan’s second CAR-T cell therapy axicabtagene ciloleucel, known as Yescarta, on December 3, while roughly endorsing corrective measures proposed by Novartis Pharma after the company’s botched the handling of its SMA...read more